268 related articles for article (PubMed ID: 34047776)
1. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.
Qi F; Cao Z; Chen B; Chai Y; Lin J; Ye J; Wei Y; Liu H; Han-Zhang H; Mao X; Feng X; Dong M
Blood Adv; 2021 Jun; 5(11):2505-2514. PubMed ID: 34047776
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas.
Hur JY; Kim YJ; Yoon SE; Son DS; Park WY; Kim SJ; Park D; Kim WS
Ann Hematol; 2020 Jun; 99(6):1293-1302. PubMed ID: 32296914
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
Rossi D; Diop F; Spaccarotella E; Monti S; Zanni M; Rasi S; Deambrogi C; Spina V; Bruscaggin A; Favini C; Serra R; Ramponi A; Boldorini R; Foà R; Gaidano G
Blood; 2017 Apr; 129(14):1947-1957. PubMed ID: 28096087
[TBL] [Abstract][Full Text] [Related]
4. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
[TBL] [Abstract][Full Text] [Related]
5. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
6. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
7. [Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension].
Liu WX; Liu YP; Jin J; Wang SL; Fang H; Ren H; Song YW; Chen B; Lu NN; Li N; Tang Y; Qi SN; Tang Y; Wang WH; Li YX
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):56-62. PubMed ID: 30678418
[No Abstract] [Full Text] [Related]
8. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
[TBL] [Abstract][Full Text] [Related]
9. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
Wei C; Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
Br J Haematol; 2023 Jul; 202(1):86-95. PubMed ID: 37132364
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer.
Gou Q; Zhang CZ; Sun ZH; Wu LG; Chen Y; Mo ZQ; Mai QC; He J; Zhou ZX; Shi F; Cui W; Zou W; Lv L; Zhuang WH; Xu RD; Li WK; Zhang J; Du HW; Xiang JX; Wang HZ; Hou T; Li ST; Li Y; Chen XM; Zhou ZJ
ESMO Open; 2021 Dec; 6(6):100275. PubMed ID: 34653800
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
13. Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA.
Sun P; Chen C; Xia Y; Wang Y; Liu PP; Bi XW; Shao YW; Ou QX; Wu X; Yang H; Nie M; Zhang XW; Li ZM; Jiang WQ
J Cancer; 2019; 10(2):323-331. PubMed ID: 30719126
[No Abstract] [Full Text] [Related]
14. Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.
Hatipoğlu T; Esmeray Sönmez E; Hu X; Yuan H; Danyeli AE; Şeyhanlı A; Önal-Süzek T; Zhang W; Akman B; Olgun A; Özkal S; Alacacıoğlu İ; Özcan MA; You H; Küçük C
Front Oncol; 2022; 12():870487. PubMed ID: 35795062
[TBL] [Abstract][Full Text] [Related]
15. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
[TBL] [Abstract][Full Text] [Related]
16. High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.
Deger T; Boers RG; de Weerd V; Angus L; van der Put MMJ; Boers JB; Azmani Z; van IJcken WFJ; Grünhagen DJ; van Dessel LF; Lolkema MPJK; Verhoef C; Sleijfer S; Martens JWM; Gribnau J; Wilting SM
Clin Epigenetics; 2021 Oct; 13(1):196. PubMed ID: 34670587
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
19. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
20. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
